IL-17A binding peptides and medical uses thereof

Patent metadata

Field	Value
Publication number	US-12358950-B2
Application number	US-202117555154-A
Country	US
Kind code	B2
Filing date	Dec 17, 2021
Priority date	Jul 27, 2018
Publication date	Jul 15, 2025
Grant date	Jul 15, 2025

Abstract

The invention relates to IL-17A binding peptides, inhibitors of the interaction of IL-17A with the receptor IL-17RA, and to bioconjugates, dimers, pharmaceutical compositions and medical use thereof.

First claim

The invention claimed is:

1. A peptide that specifically inhibits IL-17A binding to ILRA, comprising the amino acid sequence of Formula (I), wherein Formula (I) comprises an amino acid sequence selected from SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 169, SEQ ID NO: 181, SEQ ID NO: 192, SEQ ID NO: 194, SEQ ID NO: 195, SEQ ID NO: 197, SEQ ID NO: 214, SEQ ID NO: 219, SEQ ID NO: 221, SEQ ID NO: 223, SEQ ID NO: 262, or SEQ ID NO: 263.

2. The peptide of claim 1 , wherein the peptide consists of a 15 amino acid sequence.

3. A peptide that specifically inhibits IL-17A binding to ILRA, comprising the amino acid sequence of IHVTIPADLWDWINK (SEQ ID NO: 1), wherein the peptide further comprises a sequence at the C- and/or N-terminal of the peptide, wherein the peptide comprises, in order, a sequence selected from:

(a)

(SEQ ID NO: 53)

VPGDG 

(SEQ ID NO: 1)

--IHVTIPADLWDWINK,

(b)

(SEQ ID NO: 1)

IHVTIPADLWDWINK

(SEQ ID NO: 53)

--VPGDG,

(c)

(SEQ ID NO: 1)

IHVTIPADLWDWINK

(SEQ ID NO: 47)

--VPGWG,

(d)

(SEQ ID NO: 1)

IHVTIPADLWDWINK

(SEQ ID NO: 50)

--VPGAG,

(e)

(SEQ ID NO: 1)

IHVTIPADLWDWINK

(SEQ ID NO: 44)

--ARKKAAKA,

(f)

(SEQ ID NO: 47)

VPGWG

(SEQ ID NO: 1)

--IHVTIPADLWDWINK,

(g)

(SEQ ID NO: 50)

VPGAG

(SEQ ID NO: 1)

--IHVTIPADLWDWINK,

(h)

(SEQ ID NO: 1)

IHVTIPADLWDWINK

(SEQ ID NO: 49)

--VPGKG,

(i)

(SEQ ID NO: 49)

VPGKG

(SEQ ID NO: 1)

--IHVTIPADLWDWINK,

(j)

(SEQ ID NO: 44)

ARKKAAKA

(SEQ ID NO: 1)

--IHVTIPADLWDWINK,

(k)

(SEQ ID NO: 1)

IHVTIPADLWDWINK

(SEQ ID NO: 52)

--RRRRRRRR,

(1)

(SEQ ID NO: 1)

IHVTIPADLWDWINK

(SEQ ID NO: 46)

--TWWETWW,

(m)

(SEQ ID NO: 52)

RRRRRRRR

(SEQ ID NO: 1)

--IHVTIPADLWDWINK,

(n)

(SEQ ID NO: 1)

IHVTIPADLWDWINK

(SEQ ID NO: 51)

--RQIKIWFQNRRMKWKK,

or

Assignees

• Dompe Farm Spa

Inventors

• Allegretti Marcello
• Aramini Andrea
• Beccari Andrea
• Gemei Marica
• Mantelli Flavio

Classifications

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C07K2319/00

  Fusion polypeptide · CPC title

• A61P11/06

  Antiasthmatics · CPC title

• A61P19/02

  for joint disorders, e.g. arthritis, arthrosis · CPC title

• A61K38/04

  Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof ({enzyme inhibitors A61K38/005;} gastrins {A61K38/2207}, somatostatins A61K38/31, melanotropins A61K38/34 {; protease inhibitors A61K38/55}) · CPC title